Cargando…

In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. Productive SARS-CoV-2 infection relies on viral entry into cells expressing angiotensin-converting enzyme 2 (ACE2). Indeed, viral entry into ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Lapaillerie, Delphine, Charlier, Cathy, Fernandes, Henrique S., Sousa, Sergio F., Lesbats, Paul, Weigel, Pierre, Favereaux, Alexandre, Guyonnet-Duperat, Véronique, Parissi, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996581/
https://www.ncbi.nlm.nih.gov/pubmed/33669132
http://dx.doi.org/10.3390/v13030365
_version_ 1783670136168775680
author Lapaillerie, Delphine
Charlier, Cathy
Fernandes, Henrique S.
Sousa, Sergio F.
Lesbats, Paul
Weigel, Pierre
Favereaux, Alexandre
Guyonnet-Duperat, Véronique
Parissi, Vincent
author_facet Lapaillerie, Delphine
Charlier, Cathy
Fernandes, Henrique S.
Sousa, Sergio F.
Lesbats, Paul
Weigel, Pierre
Favereaux, Alexandre
Guyonnet-Duperat, Véronique
Parissi, Vincent
author_sort Lapaillerie, Delphine
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. Productive SARS-CoV-2 infection relies on viral entry into cells expressing angiotensin-converting enzyme 2 (ACE2). Indeed, viral entry into cells is mostly mediated by the early interaction between the viral spike protein S and its ACE2 receptor. The S/ACE2 complex is, thus, the first contact point between the incoming virus and its cellular target; consequently, it has been considered an attractive therapeutic target. To further characterize this interaction and the cellular processes engaged in the entry step of the virus, we set up various in silico, in vitro and in cellulo approaches that allowed us to specifically monitor the S/ACE2 association. We report here a computational model of the SARS-CoV-2 S/ACE2 complex, as well as its biochemical and biophysical monitoring using pulldown, AlphaLISA and biolayer interferometry (BLI) binding assays. This led us to determine the kinetic parameters of the S/ACE2 association and dissociation steps. In parallel to these in vitro approaches, we developed in cellulo transduction assays using SARS-CoV-2 pseudotyped lentiviral vectors and HEK293T-ACE2 cell lines generated in-house. This allowed us to recapitulate the early replication stage of the infection mediated by the S/ACE2 interaction and to detect cell fusion induced by the interaction. Finally, a cell imaging system was set up to directly monitor the S/ACE2 interaction in a cellular context and a flow cytometry assay was developed to quantify this association at the cell surface. Together, these different approaches are available for both basic and clinical research, aiming to characterize the entry step of the original SARS-CoV-2 strain and its variants as well as to investigate the possible chemical modulation of this interaction. All these models will help in identifying new antiviral agents and new chemical tools for dissecting the virus entry step.
format Online
Article
Text
id pubmed-7996581
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79965812021-03-27 In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion Lapaillerie, Delphine Charlier, Cathy Fernandes, Henrique S. Sousa, Sergio F. Lesbats, Paul Weigel, Pierre Favereaux, Alexandre Guyonnet-Duperat, Véronique Parissi, Vincent Viruses Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. Productive SARS-CoV-2 infection relies on viral entry into cells expressing angiotensin-converting enzyme 2 (ACE2). Indeed, viral entry into cells is mostly mediated by the early interaction between the viral spike protein S and its ACE2 receptor. The S/ACE2 complex is, thus, the first contact point between the incoming virus and its cellular target; consequently, it has been considered an attractive therapeutic target. To further characterize this interaction and the cellular processes engaged in the entry step of the virus, we set up various in silico, in vitro and in cellulo approaches that allowed us to specifically monitor the S/ACE2 association. We report here a computational model of the SARS-CoV-2 S/ACE2 complex, as well as its biochemical and biophysical monitoring using pulldown, AlphaLISA and biolayer interferometry (BLI) binding assays. This led us to determine the kinetic parameters of the S/ACE2 association and dissociation steps. In parallel to these in vitro approaches, we developed in cellulo transduction assays using SARS-CoV-2 pseudotyped lentiviral vectors and HEK293T-ACE2 cell lines generated in-house. This allowed us to recapitulate the early replication stage of the infection mediated by the S/ACE2 interaction and to detect cell fusion induced by the interaction. Finally, a cell imaging system was set up to directly monitor the S/ACE2 interaction in a cellular context and a flow cytometry assay was developed to quantify this association at the cell surface. Together, these different approaches are available for both basic and clinical research, aiming to characterize the entry step of the original SARS-CoV-2 strain and its variants as well as to investigate the possible chemical modulation of this interaction. All these models will help in identifying new antiviral agents and new chemical tools for dissecting the virus entry step. MDPI 2021-02-25 /pmc/articles/PMC7996581/ /pubmed/33669132 http://dx.doi.org/10.3390/v13030365 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Lapaillerie, Delphine
Charlier, Cathy
Fernandes, Henrique S.
Sousa, Sergio F.
Lesbats, Paul
Weigel, Pierre
Favereaux, Alexandre
Guyonnet-Duperat, Véronique
Parissi, Vincent
In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
title In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
title_full In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
title_fullStr In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
title_full_unstemmed In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
title_short In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
title_sort in silico, in vitro and in cellulo models for monitoring sars-cov-2 spike/human ace2 complex, viral entry and cell fusion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996581/
https://www.ncbi.nlm.nih.gov/pubmed/33669132
http://dx.doi.org/10.3390/v13030365
work_keys_str_mv AT lapailleriedelphine insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion
AT charliercathy insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion
AT fernandeshenriques insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion
AT sousasergiof insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion
AT lesbatspaul insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion
AT weigelpierre insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion
AT favereauxalexandre insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion
AT guyonnetduperatveronique insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion
AT parissivincent insilicoinvitroandincellulomodelsformonitoringsarscov2spikehumanace2complexviralentryandcellfusion